natgillin/translations-raw huggingface dataset:
• Patienter, der tidligere har haft intrakraniel blødning (ICH). 
• Patients with a history of intracranial haemorrhage (ICH).
Varigheden af trombocythæmningen er dosis- og koncentrationsafhængig. 
The duration of platelet inhibition is dose and concentration dependent.
Gastritis, gastrointestinal blødning, gingival blødning, melæna, rektalblødning 
Gastritis, Gastrointestinal haemorrhage, Gingival bleeding, Melaena, Rectal haemorrhage
Blødningssygdomme i anamnesen og samtidig brug af visse typer medicin (f.eks. behandling med antikoagulantia og fibrinolytika og nonsteroide antiinflammatoriske lægemidler til kronisk behandling (NSAID), selektive serotonin-reuptake-hæmmere, serotonin-noradrenalinreuptake-hæmmere) kan ligeledes øge risikoen for blødning hos patienter, der tager Zontivity. 
A history of bleeding disorders and use of certain concomitant medicinal products (e.g., anticoagulant and fibrinolytic therapy, and chronic nonsteroidal anti-inflammatory drugs (NSAIDS), selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors) may also increase the risk of bleeding in patients taking Zontivity.
Letal blødning 
Fatal Bleeding
Vorapaxar var ikke mutagent elle genotoksisk i en serie af in vitro- og in vivo-studier. 
Vorapaxar was not mutagenic or genotoxic in a battery of in vitro and in vivo studies.
Trafik- og arbejdssikkerhed Det forventes ikke, at Zontivity påvirker evnen til at køre eller til at bruge maskiner. 
Driving and using machines Zontivity is not likely to affect your ability to drive or use machines.
Der blev ikke observeret klinisk relevante forskelle i farmakokinetikken for vorapaxar efter daglig samtidig anvendelse af et antacidum indeholdende aluminiumhydroxid/magnesiumcarbonat eller pantoprazol (en protonpumpehæmmer). 
No clinically relevant differences in vorapaxar pharmacokinetics were observed following daily co-administration of an aluminium hydroxide/magnesium carbonate antacid or pantoprazole (a proton pump inhibitor).
Der findes ingen kendt behandling til at reversere Zontivitys trombocytfunktionshæmmende effekt. 
There is no known treatment to reverse the antiplatelet effect of Zontivity.
In vitro-metabolismestudier viser, at det er usandsynligt, at vorapaxar forårsager klinisk signifikant hæmning af human CYP1A2, CYP2B6, CYP3A, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6. 
In vitro metabolism studies demonstrate that vorapaxar is unlikely to cause clinically significant inhibition of human CYP1A2, CYP2B6, CYP3A, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.
Transfusion af trombocytter kan overvejes som understøttende behandling, hvis der forekommer blødning (se pkt. 
Platelet transfusion may be considered as supportive therapy should bleeding occur (see section 5.3).
Den gennemsnitlige estimerede Cmax og AUC for vorapaxar var 24% og 22% højere hos asiatiske patienter sammenlignet med kaukasere. 
The mean estimated vorapaxar Cmax and AUC were 24% and 22% higher in Asian patients compared to that of Caucasians.
• ritonavir, nelfinavir, indinavir, saquinavir (medicin til behandling af hiv og aids) 
• ritonavir, nelfinavir, indinavir, saquinavir (used to treat HIV-AIDS)
De blødningsrelaterede bivirkninger i tabel 1 er opsummeret for TRA 2°P TIMI 50-studiet. 
The adverse reactions of bleeding in Table 1 are summarized for the TRA 2°P TIMI 50 study.
Blodplader er blodlegemer, som hjælper til med at få blodet til at størkne. 
Platelets are blood cells that help with normal blood clotting.
• itraconazol, ketoconazol, posaconazol (medicin til behandling af svampeinfektioner) 
• itraconazole, ketoconazole, posaconazole (used to treat fungal infections)
Dosisjustering af vorapaxar er ikke nødvendig hos patienter, der tager svage eller moderate CYP3A-hæmmere. 
No dose adjustment for vorapaxar is required in patients taking weak to moderate inhibitors of CYP3A.
Seponering af Zontivity 
Discontinuation of Zontivity
Den gennemsnitlige estimerede Cmax og AUC for vorapaxar var henholdsvis 30% og 32% højere hos kvinder sammenlignet med mænd. 
The mean estimated vorapaxar Cmax and AUC were 30% and 32% higher, respectively, in females compared to males.
Blandt post-MI- og PAD-patienter uden apopleksi eller TCI i anamnesen syntes Zontivity at reducere raten af definitiv stenttrombose (HR: 0,71 (0,51-0,99) for bedømmelsen “definitiv”) versus placebo hos forsøgspersoner, der fik nogen form for stent før eller under studiet. 
Among post-MI or PAD patients without a history of stroke or TIA, Zontivity appeared to reduce the rate of definite stent thrombosis (HR 0.71 (0.51-0.99 for adjudicated “definite”) vs. placebo in subjects receiving any stent before or during the study.
Det mediane BMI var 27. 
The median Body Mass Index was 27.
• clarithromycin, telithromycin (medicin til behandling af infektioner) 
• clarithromycin, telithromycin (used to treat infections)
Samtidig anvendelse af et antacidum indeholdende aluminiumhydroxid/magnesiumcarbonat eller en protonpumpehæmmer (pantoprazol) påvirkede ikke AUC for vorapaxar og resulterede i et mindre fald i Cmax. 
Co-administration of an aluminium hydroxide/magnesium carbonate antacid or proton pump inhibitor (pantoprazole) did not affect vorapaxar AUC with only small decreases in Cmax.
Hos post-MI- og PAD-patienter uden apopleksi eller TCI i anamnesen indikerede en analyse af gentagne forekomster af endepunkter, bekræftet af en uafhængig komite, at Zontivity var associeret med en reduktion i incidensen af recidiverende hændelser. 
In post-MI or PAD patients with no history of stroke or TIA, an analysis of multiple occurrences of adjudicated endpoints indicates that Zontivity was associated with a reduction in the incidence of recurrent events.
I studier med raske forsøgspersoner forekom der ingen ændringer i ekspression af trombocyt Pselectin og opløselig CD40 ligand (sCD40L) eller koagulationstestparametre (TT, PT, aPTT, ACT, ECT) efter administration af vorapaxar som enkelt- eller flerdosis (28 dage). 
In healthy volunteer studies, no changes in platelet P-selectin and soluble CD40 ligand (sCD40L) expression or coagulation test parameters (TT, PT, aPTT, ACT, ECT) occurred after single or multiple dose (28 days) administration of vorapaxar.
I toksicitetsstudier med gentagne orale doser hos gnavere og aber var de vigtigste behandlingsrelaterede fund hyperplasi af urinblæren og urinlederne hos mus, blodpropper i leverblodkar, lymfoid nekrose og dannelse af blærer (vakuoler) i nethinden hos rotter og fosfolipidose hos alle arter. 
In repeat dose oral toxicity studies in rodents and monkeys, the principal treatment-related findings were urinary bladder and ureter hyperplasia in mice, hepatic vascular thrombi, lymphoid necrosis and retinal vacuolation in rats and phospholipidosis in all species.
Den kliniske evidens for Zontivitys virkning hos patienter med myokardieinfarkt i anamnesen, defineret som et spontant MI ≥2 uger siden, men inden for 12 måneder, er udledt fra TRA 2°P - TIMI 50-studiet (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events). 
The clinical evidence for the effect of Zontivity in patients with a history of myocardial infarction, defined as a spontaneous MI ≥2 weeks but 12 months prior, is derived from TRA 2°P - TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events).
Derudover hæmmer vorapaxar trombin-receptor-agonist-peptid (TRAP)-induceret trombocytaggregation uden at påvirke koagulationsparametre. 
In addition, vorapaxar inhibits thrombin receptor agonist peptide (TRAP)-induced platelet aggregation without affecting coagulation parameters.
På basis af prækliniske studier, som undersøgte blødning, mens patienten var i behandling med vorapaxar og i samtidig baggrundsbehandling med acetylsalicylsyre og clopidogrel, er det måske muligt at genoprette hæmostase ved at administrere eksogene trombocytter (se pkt. 
Based on results of pre-clinical studies that investigated bleeding while on vorapaxar on the background of acetylsalicylic acid and clopidogrel, it may be possible to restore hemostasis by administering exogenous platelets.
Samtidig administration af vorapaxar (40 mg) og digoxin (0,5 mg enkeltdosis) øgede Cmax og AUC for digoxin med henholdsvis 54% og 5%. 
Co-administration of vorapaxar (40 mg) and digoxin (0.5 mg single-dose) increased digoxin Cmax and AUC by 54% and 5%, respectively.
I TRACER-studiet (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), inkluderende patienter med NSTE-AKS (akut koronart syndrom (AKS) uden elevation af ST-segmentet i ekg (NSTE)), som overvejende ikke havde været i trombocytfunktionshæmmende behandling, opnåede vorapaxar, med en startdosis på 40 mg og en vedligeholdelsesdosis på 2,5 mg/dag som tillæg til standardbehandling, som blev påbegyndt inden for 24 timer efter NSTEAKS, ikke dets primære endepunkt (kardiovaskulær død, MI, apopleksi, akut koronar revaskularisering og recidiverende iskæmi med genindlæggelse), og der var en øget risiko for moderat eller svær blødning i henhold til GUSTO. 
In the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, comprising patients with a NSTEACS (non-ST segment elevation acute coronary syndrome) who were largely antiplatelet naive, vorapaxar, with a loading dose of 40 mg and then maintained at 2.5 mg/day in addition to standard of care, initiated within 24 hours of NSTEACS, did not achieve its primary efficacy endpoint (cardiovascular death, MI, stroke, urgent coronary revascularization, and recurrent ischemia with rehospitalisation) and there was an increased risk of GUSTO moderate or severe bleeding.
Patienter, der tager Zontivity, skal også tage acetylsalicylsyre eller clopidogrel i henhold til indikationerne herfor eller standardbehandling. 
Patients taking Zontivity should also take acetylsalicylic acid or clopidogrel according to their indications or standard of care.
Der er begrænset terapeutisk erfaring hos patienter med svært nedsat nyrefunktion eller terminal nyresygdom. 
There is limited therapeutic experience in patients with severe renal impairment or end stage renal disease.
Der foreligger ingen data om indvirkningen af Zontivity på fertilitet hos mennesker. 
There are no data on fertility in humans administered Zontivity.
På basis af en farmakokinetisk populationsanalyse med data fra raske forsøgspersoner og patienter med aterosklerose estimeres vorapaxars gennemsnitlige AUC at være højere hos patienter med let (17%) og moderat (34%) nedsat nyrefunktion sammenlignet med patienter med normal nyrefunktion. 
Based on population pharmacokinetic analysis using data from healthy subjects and patients with atherosclerotic disease, vorapaxar mean AUC is estimated to be higher in patients with mild (17%) and moderate (34%) renal impairment compared to those with normal renal function; these differences are not considered to be clinically relevant.
Primært virkningsendepunkt (CV-død/MI/ apopleksi/UCR) CV-død 
Primary Efficacy Endpoint (CV death/MI/stroke/UCR) CV Death
Det er påvist, at Zontivity reducerer hyppigheden af det kombinerede endepunkt kardiovaskulær (CV) død, myokardieinfarkt (MI), apopleksi og akut koronar revaskularisering (UCR). 
Zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).
I kohorten med post-MI- og PAD-patienter uden apopleksi eller TCI i anamnesen er resultaterne for det primære sammensatte endepunkt og det centrale sekundære sammensatte endepunkt i overensstemmelse med resultatet i den samlede population (se figur 1 og tabel 4). 
In the cohort of post-MI or PAD patients with no history of stroke or TIA, the findings for the primary and key secondary composite endpoints are consistent with the overall population (see Figure 1 and Table 4).
Selvom TRA 2°P - TIMI 50-studiet ikke var designet med henblik på at vurdere den relative gavn af Zontivity i de enkelte patientundergrupper, var den gavnlige virkning mest tydelig hos patienter, som blev inkluderet på basis af et nyligt myokardieinfarkt (MI), defineret ved spontant MI ≥2 uger siden, men inden for 12 måneder (post-MI- eller PAD-patientpopulation) uden apopleksi eller TCI i anamnesen. 
Although the TRA 2°P - TIMI 50 trial was not designed to evaluate the relative benefit of Zontivity in individual patient subgroups, the benefit was most apparent in patients who were enrolled on the basis of a recent MI as indicated by a history of spontaneous MI ≥2 weeks but 12 months prior (post-MI or PAD patient population) with no history of stroke or TIA.
Dosisjustering er ikke nødvendig for patienter med nedsat nyrefunktion, herunder forsøgspersoner med ESRD. 
No dose adjustment is necessary for patients with renal impairment, including subjects with ESRD.
• hvis du skal have foretaget en planlagt operation, herunder tandoperation 
• plan to have surgery including dental surgery
• hvis du for nylig har haft blødning fra maven eller tarmen 
• have had recent bleeding from the stomach or gut
Kontakt straks din læge, hvis du får et eller flere af disse sjældne symptomer på et slagtilfælde : 
Call your doctor straight away if you have any of these symptoms of a stroke, which is uncommon:
Når Zontivity blev administreret som tillæg til standardbehandling, normalt acetylsalicylsyre og et thienopyridin, øgede Zontivity risikoen for GUSTO (Global utilization of streptokinase and tpa for occluded arteries) moderat eller svær blødning sammenlignet med standardbehandling alene (se pkt. 
When administered in addition to standard care, generally acetylsalicylic acid and a thienopyridine, compared with standard care alone, Zontivity increased the risk of GUSTO (Global utilization of streptokinase and tpa for occluded arteries) moderate or severe bleeding (see section 4.8).
Zontivity skal anvendes med forsigtighed hos patienter med moderat nedsat leverfunktion. 
Zontivity should be used with caution in patients with moderate hepatic impairment.
Der forventes ingen klinisk betydningsfuld hæmning af CYP2B6, CYP3A, CYP2C19 eller CYP2D6 via M20. 
No clinically meaningful inhibition of CYP2B6, CYP3A, CYP2C19, or CYP2D6 by M20 is expected.
Resultatet for det centrale sekundære endepunkt, 3-års K-M-event rate på 9,3% i Zontivity-gruppen, var sammenligneligt med resultatet på 10,5% i placebogruppen (HR: 0,87; 95% CI, 0,80 til 0,94; p <0,001). 
The findings for the key secondary efficacy endpoint, a 3-year K-M event rate of 9.3% in the Zontivity group compared with that of 10.5% in placebo group (HR: 0.87; 95% CI, 0.80 to 0.94; p <0.001).
Figur 1: Tid til første forekomst af CV-død, MI, apopleksi eller UCR hos post-MI- og PADpatienter uden apopleksi eller TCI i anamnesen 
Figure 1: Time to First Occurrence of CV death, MI, Stroke or UCR in Post-MI or PAD Patients with No History of Stroke or TIA
Hos post-MI- og PAD-patienter uden apopleksi eller TCI i anamnesen var 3-års K-M-event rate for ICH henholdsvis 0, 6% og 0,5% for Zontivity plus standardbehandling og standardbehandling alene. 
In post-MI or PAD patients with no history of stroke or TIA, the 3 year K-M event rates for ICH were 0.6% and 0.5% for Zontivity plus standard care and standard care alone, respectively.
Samtidig brug af vorapaxar og warfarin eller andre orale antikoagulantia kan øge risikoen for blødning og derfor frarådes dette. 
The combination of vorapaxar with warfarin or other oral anticoagulants may increase the risk of bleeding and should be avoided.
• Patienter med aktiv patologisk blødning (se pkt. 
• Patients with any active pathological bleeding (see sections 4.4 and 4.8).
Endepunkter 
Endpoints
Af patienterne med MI uden apopleksi eller TCI i anamnesen var 21% i behandling med acetylsalicylsyre uden thienopyridin, 1% var i behandling med et thienopyridin uden acetylsalicylsyre, og 77% fik både acetylsalicylsyre og et thienopyridin, da de blev inkluderet i studiet. 
Of the patients with MI without a history of stroke or TIA, 21% were receiving acetylsalicylic acid without thienopyridine, 1% was receiving a thienopyridine without acetylsalicylic acid, and 77% were receiving both acetylsalicylic acid and a thienopyridine when they enrolled in the trial.
Vorapaxar er bundet med høj affinitet til humant serumalbumin og fordeles ikke fortrinsvis i erytrocytter. 
Vorapaxar is highly bound to human serum albumin and does not preferentially distribute into red blood cells.
Resultaterne for det primære sammensatte endepunkt viser en 3-års Kaplan-Meier (K-M)-event rate på 11,2% i Zontivity-gruppen sammenlignet med 12,4% i placebogruppen (Hazard ratio [HR]: 0,88; 95% konfidensinterval [CI], 0,82 til 0,95; p=0,001) og påviste superioritet af Zontivity i forhold til placebo med hensyn til at forebygge CV-død, MI, apopleksi eller UCR. 
The findings for the primary efficacy composite endpoint show a 3-year Kaplan-Meier (K-M) event rate of 11.2% in the Zontivity group compared with that of 12.4% in the placebo group (Hazard Ratio [HR]: 0.88; 95% Confidence Interval [CI], 0.82 to 0.95; p=0.001) and demonstrated superiority of Zontivity over placebo in preventing CV death, MI, stroke, or UCR.
Tag ikke Zontivity, hvis du samtidigt er i behandling med prasugrel eller ticagrelor (andre blodpladehæmmende midler). 
Do not take Zontivity if you are currently being treated with prasugrel or ticagrelor (other anti-platelet agents).
• digoxin (medicin til behandling af hjertesvigt) 
• digoxin (used to treat heart failure)
Pakninger med 7, 28, 30 og 100 tabletter i aluminiumblisterkort. 
Packs of 7, 28, 30 and 100 tablets in aluminium blister cards.
PAD-patientpopulationen uden apopleksi eller TCI i anamnesen bestod af 90% kaukasere, 29% var kvinder og 57% ≥65 år, medianalderen var 66 år, og inkluderede patienter med diabetes (35%) og patienter med hypertension (82%). 
The PAD patient population with no history of stroke or TIA was 90% Caucasian, 29% female, and 57% ≥65 years of age, with a median age of 66 years, and included patients with diabetes (35%) and patients with hypertension (82%).
Patienter, som får akut koronarsyndrom (AKS), mens de er i behandling med Zontivity, kan fortsætte behandlingen med Zontivity. 
Patients experiencing acute coronary syndrome (ACS) while on Zontivity can remain on Zontivity.
• warfarin, andre orale blodfortyndende midler, heparin eller lavmolekylært heparin 
• warfarin, other oral anticoagulants, heparin, or low molecular weight heparin (blood thinner medicines)
Post-MI-patientpopulationen uden apopleksi eller TCI i anamnesen bestod af 88% kaukasere, 20% var kvinder og 29% ≥65 år, medianalderen var 58 år, og inkluderede patienter med diabetes (21%) og patienter med hypertension (62%). 
The post-MI patient population with no history of stroke or TIA was 88% Caucasian, 20% female, and 29% ≥65 years of age, with a median age of 58 years, and included patients with diabetes (21%) and patients with hypertension (62%).
Samtidig administration af Zontivity og antikoagulantia, f.eks. warfarin og nye orale antikoagulantia (NOAC), frarådes (se pkt. 
The coadministration of Zontivity with anticoagulants e.g., warfarin and new oral anticoagulants (NOACs), should be avoided.
Zontivity er kontraindiceret hos patienter med svært nedsat leverfunktion (Child-Pugh, 10 til 15 point) (se pkt. 
Zontivity is contraindicated in patients with severe hepatic impairment (Child Pugh, 10 to 15 points) (see sections 4.3 and 4.4).
Behandlingen med Zontivity skal initieres mindst 2 uger efter et myokardieinfarkt (MI) og preferentielt inden for de første 12 måneder efter den akutte hændelse (se pkt. 
Zontivity should be initiated at least 2 weeks after a MI and preferably within the first 12 months from the acute event (see section 5.1).
Hvis noget af ovenstående gælder for dig, eller hvis du er i tvivl, så spørg lægen, apotekspersonalet eller sundhedspersonalet, før du tager Zontivity. 
If any of the above apply to you, or if you are not sure, talk to your doctor, pharmacist, or nurse before taking Zontivity.
Du og din læge skal beslutte, om du skal tage Zontivity eller ej. 
You and your doctor will decide if you will take Zontivity.
Gule, ovale, filmovertrukne tabletter, 8,48 mm x 4,76 mm, med “351” præget på den ene side og MSD-logoet på den anden side. 
The film-coated tablets are yellow, oval-shaped, size 8.48 mm x 4.76 mm, with “351” on one side and the MSD logo on the other side.
De ikke-blødningsrelaterede bivirkninger i tabel 1 er opsummeret for både TRA 2°P TIMI 50-studiet og TRACER-studiet (se tabel 1). 
Non-bleeding adverse reactions in Table 1 are summarized for both the TRA 2°P TIMI 50 and TRACER studies.
Af patienterne med PAD uden apopleksi eller TCI i anamnesen fik 61% acetylsalicylsyre uden thienopyridin, 8% fik et thienopyridin uden acetylsalicylsyre, og 27% fik både acetylsalicylsyre og et thienopyridin, da de blev inkluderet i studiet. 
Of the patients with PAD without a history of stroke or TIA, 61% were receiving acetylsalicylic acid without thienopyridine, 8% were receiving a thienopyridine without acetylsalicylic acid, and 27% were receiving both acetylsalicylic acid and a thienopyridine when they enrolled.
Din læge vil beslutte, om du også skal tage acetylsalicylsyre og/eller clopidogrel, mens du tager Zontivity. 
Your doctor will determine if you should also take aspirin, clopidogrel, or both, while taking Zontivity.
Hændelser i alt 
Total Events
Mindre blødning i henhold til TIMI: Klinisk tydelig blødning med et fald på 30-50 g/l i hæmoglobin. 
TIMI Minor: Clinically apparent with 30-50 g/L decrease in haemoglobin.
• carbamazepin, phenytoin (krampestillende medicin til behandling af epilepsi) 
• carbamazepine, phenytoin (anti-seizure medicines)
I TRA 2°P - TIMI 50 fik 367 post-MI- eller PAD-patienter uden apopleksi eller TCI i anamnesen foretaget bypassoperation (CABG). 
In TRA 2°P - TIMI 50, 367 post-MI or PAD patients with no history of stroke or TIA underwent CABG surgery.
Vorapaxar absorberes hurtigt efter oral administration af en enkeltdosis vorapaxarsulfat på 2,5 mg, og maksimalkoncentrationen forekommer ved en gennemsnitlig tmax på 1 time (interval: 1 til 2) i fastende tilstand. 
After oral administration of a single vorapaxar sulfate 2.5 mg dose, vorapaxar is rapidly absorbed and peak concentrations occur at a median tmax of 1 hour (range: 1 to 2) under fasted conditions.
Konjunktivalblødning, diplopi (dobbeltsyn) 
Conjunctival haemorrhage, diplopia
Der er begrænset klinisk erfaring med prasugrel og ingen erfaring med ticagrelor i fase III-studierne. 
There is limited clinical experience with prasugrel and no experience with ticagrelor in the Phase 3 studies.
Hos patienter i behandling med vorapaxar kan samtidig brug af heparin (herunder lavmolekylært heparin (LMWH)) associeres med øget risiko for blødning, og forsigtighed tilrådes. 
In patients treated with vorapaxar the concomitant use of heparin (including low molecular weight heparin (LMWH)) might be associated with an increased risk of bleeding and caution is advised.
Resultaterne for blødningsendepunkterne hos post-MI- eller PAD-patienter uden apopleksi eller TCI i anamnesen er vist i tabel 2. 
The results for the bleeding endpoints in the post-MI or PAD patients with no history of stroke or TIA are shown in Table 2.
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, før du tager Zontivity: 
Talk to your doctor, pharmacist, or nurse before taking Zontivity if you:
Blandt de patienter, som indtrådte i TRA 2°P - TIMI 50-studiet, havde patienterne med iskæmisk apopleksi i anamnesen en højere 3-års K-M-event rate for ICH, såfremt de fik Zontivity plus standardbehandling (2,7%) sammenlignet med standardbehandling alene (0,9%). 
In TRA 2°P - TIMI 50, among patients who entered the trial, those with a history of ischaemic stroke had a higher 3 year K-M event rate for ICH on Zontivity plus standard care (2.7%) than on standard care alone (0.9%).
Pakninger med 7, 28, 30 og 100 filmovertrukne tabletter i aluminium/aluminiumblisterkort. 
Packs of 7, 28, 30 and 100 film-coated tablets in aluminium/aluminium blister cards.
Der er begrænset erfaring med prasugrel og ingen erfaring med ticagrelor i fase III-studierne med vorapaxar. 
There is limited experience with prasugrel and no experience with ticagrelor in the vorapaxar Phase 3 studies.